ADAG AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
ADAG Current Performance
-0.40%
Adagene inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ADAG
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ELEV | Elevation oncology inc | - | 2 | 2 | 2 | 1 | |
CRBP | Corbus pharmaceuticals holdings inc | 2 | 4 | 2 | 3 | 1 | |
SGMT | Sagimet biosciences inc | - | 1 | 3 | 2 | 1 | |
AMRN | Amarin corporation plc | 2 | 3 | 3 | 1 | 1 | |
CVKD | Cadrenal therapeutics inc | - | 2 | 2 | 1 | 1 |
- ELEV Elevation oncology incValue -Trend 2Swing Trading 2Whale Interest 2Dividend 1See more
ADAG Profile
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company's main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.